The role of micrornas in diabetic complications—special emphasis on wound healing

Genes

Volumn 5, Issue 4, 2014, Pages 926-956

  Moura, João ^a   Børsheim, Elisabet ^b,c,d,e   Carvalho, Eugenia ^a,b,c,f  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b Arkansas Children's Nutrition Center   (United States)

^c ARKANSAS CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f The Portuguese Diabetes Association (APDP)   (Portugal)

Author keywords

Diabetes; Diagnostic biomarkers; Inflammation; Macrovascular and microvascular complications; MicroRNA; Skin; Therapeutic targets; Vascular disease; Wound healing

Indexed keywords

ANTAGOMIR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MICRORNA; MICRORNA 1; MICRORNA 106A; MICRORNA 126; MICRORNA 132; MICRORNA 133A; MICRORNA 140 3P; MICRORNA 143; MICRORNA 144 3P; MICRORNA 146; MICRORNA 155; MICRORNA 16; MICRORNA 195; MICRORNA 198; MICRORNA 200B; MICRORNA 203; MICRORNA 206; MICRORNA 21; MICRORNA 22; MICRORNA 223; MICRORNA 26A; MICRORNA 29B; MICRORNA 34A; MICRORNA 492; MICRORNA 548C; MICRORNA 548I; MICRORNA 99; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROSIS; CELL PROLIFERATION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFECT; GENE EXPRESSION; HUMAN; INFLAMMATION; LEG AMPUTATION; NONHUMAN; PATHOGENESIS; REVIEW; WOUND CLOSURE; WOUND HEALING; WOUND HEALING IMPAIRMENT;

EID: 84919594907     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes5040926     Document Type: Review

References (227)

1. Chen, L.; Magliano, D.J.; Zimmet, P.Z. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat. Rev. Endocrinol. 2012, 8, 228-236.
2. Whiting, D.R.; Guariguata, L.; Weil, C.; Shaw, J. Idf diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 2011, 94, 311-321.
3. Moura, L.I.; Dias, A.M.; Carvalho, E.; de Sousa, H.C. Recent advances on the development of wound dressings for diabetic foot ulcer treatment—A review. Acta Biomater. 2013, 9, 7093-7114.
4. Reaven, G.M. Pathophysiology of insulin resistance in human disease. Physiol. Rev. 1995, 75, 473-486.
5. DeFronzo, R.A.; Bonadonna, R.C.; Ferrannini, E. Pathogenesis of niddm. A balanced overview. Diabetes Care 1992, 15, 318-368.
6. Fontbonne, A.; Eschwege, E.; Cambien, F.; Richard, J.L.; Ducimetiere, P.; Thibult, N.; Warnet, J.M.; Claude, J.R.; Rosselin, G.E. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the paris prospective study. Diabetologia 1989, 32, 300-304.
7. Srikanth, S.; Deedwania, P. Primary and secondary prevention strategy for cardiovascular disease in diabetes mellitus. Cardiol. Clin. 2011, 29, 47-70.
8. Yun, J.S.; Ko, S.H.; Kim, J.H.; Moon, K.W.; Park, Y.M.; Yoo, K.D.; Ahn, Y.B. Diabetic retinopathy and endothelial dysfunction in patients with type 2 diabetes mellitus. Diabetes Metab. J. 2013, 37, 262-269.
9. Klein, R.; Moss, S.E.; Klein, B.E.; Davis, M.D.; DeMets, D.L. Wisconsin epidemiologic study of diabetic retinopathy. XII. Relationship of c-peptide and diabetic retinopathy. Diabetes 1990, 39, 1445-1450.
10. Andersen, A.R.; Christiansen, J.S.; Andersen, J.K.; Kreiner, S.; Deckert, T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. Diabetologia 1983, 25, 496-501.
11. Higgins, G.C.; Coughlan, M.T. Mitochondrial dysfunction and mitophagy: The beginning and end to diabetic nephropathy? Br. J. Pharmacol. 2014, 171, 1917-1942.
12. Kim, S.K.; Lee, K.J.; Hahm, J.R.; Lee, S.M.; Jung, T.S.; Jung, J.H.; Kim, S.; Kim, D.R.; Ahn, S.K.; Choi, W.H., et al. Clinical significance of the presence of autonomic and vestibular dysfunction in diabetic patients with peripheral neuropathy. Diabetes Metab. J. 2012, 36, 64-69.
13. Da Silva, L.; Carvalho, E.; Cruz, M.T. Role of neuropeptides in skin inflammation and its involvement in diabetic wound healing. Expert Opin. Biol. Ther. 2010, 10, 1427-1439.
14. Hata, J.; Arima, H.; Zoungas, S.; Fulcher, G.; Pollock, C.; Adams, M.; Watson, J.; Joshi, R.; Kengne, A.P.; Ninomiya, T., et al. Effects of the endpoint adjudication process on the results of a randomised controlled trial: The advance trial. PLoS ONE 2013, 8, e55807.
15. O’Connor, P.J.; Ismail-Beigi, F. Near-normalization of glucose and microvascular diabetes complications: Data from accord and advance. Ther. Adv. Endocrinol. Metab. 2011, 2, 17-26.
16. Bianchi, C.; Del Prato, S. Metabolic memory and individual treatment aims in type 2 diabetes-outcome-lessons learned from large clinical trials. Rev. Diabet. Stud. 2011, 8, 432-440.
17. Holman, R.R.; Paul, S.K.; Bethel, M.A.; Matthews, D.R.; Neil, H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008, 359, 1577-1589.
18. Gaede, P.; Lund-Andersen, H.; Parving, H.H.; Pedersen, O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 2008, 358, 580-591.
19. Ambros, V. The functions of animal microRNAs. Nature 2004, 431, 350-355.
20. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215-233.
21. Maqbool, R.; Hussain, M.U. MicroRNAs and human diseases: Diagnostic and therapeutic potential. Cell Tissue Res. 2014, doi:10.1007/s00441-013-1787-3.
22. Ardekani, A.M.; Naeini, M.M. The role of microRNAs in human diseases. Avicenna J. Med. Biotechnol. 2010, 2, 161-179.
23. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843-854.
24. Pillai, R.S.; Bhattacharyya, S.N.; Filipowicz, W. Repression of protein synthesis by miRNAs: How many mechanisms? Trends Cell Biol. 2007, 17, 118-126.
25. Li, L.C.; Okino, S.T.; Zhao, H.; Pookot, D.; Place, R.F.; Urakami, S.; Enokida, H.; Dahiya, R. Small dsRNAs induce transcriptional activation in human cells. Proc. Natl. Acad. Sci. USA 2006, 103, 17337-17342.
26. Vasudevan, S.; Tong, Y.; Steitz, J.A. Switching from repression to activation: MicroRNAs can up-regulate translation. Science 2007, 318, 1931-1934.
27. Chew, B.H.; Ghazali, S.S.; Ismail, M.; Haniff, J.; Bujang, M.A. Age 60 years was an independent risk factor for diabetes-related complications despite good control of cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp. Gerontol. 2013, 48, 485-491.
28. Djaberi, R.; Beishuizen, E.D.; Pereira, A.M.; Rabelink, T.J.; Smit, J.W.; Tamsma, J.T.; Huisman, M.V.; Jukema, J.W. Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus. Diabetologia 2008, 51, 1581-1593.
29. Rawal, S.; Manning, P.; Katare, R. Cardiovascular microRNAs: As modulators and diagnostic biomarkers of diabetic heart disease. Cardiovasc. Diabetol. 2014, 13, 44.
30. Cheng, J.; Zhang, W.; Zhang, X.; Han, F.; Li, X.; He, X.; Li, Q.; Chen, J. Effect of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: A meta-analysis. JAMA Intern. Med. 2014, 174, 773-785.
31. Davis, T.M.; Coleman, R.L.; Holman, R.R.; Group, U. Ethnicity and long-term vascular outcomes in type 2 diabetes: A prospective observational study (UKPDS 83). Diabetic Med. 2014, 31, 200-207.
32. McClelland, A.D.; Kantharidis, P. MicroRNA in the development of diabetic complications. Clin. Sci. 2014, 126, 95-110.
33. Kantharidis, P.; Wang, B.; Carew, R.M.; Lan, H.Y. Diabetes complications: The microRNA perspective. Diabetes 2011, 60, 1832-1837.
34. Sayed, A.S.; Xia, K.; Salma, U.; Yang, T.; Peng, J. Diagnosis, prognosis and therapeutic role of circulating miRNAs in cardiovascular diseases. Heart Lung Circ. 2014, 23, 503-510.
35. De Rosa, S.; Curcio, A.; Indolfi, C. Emerging role of microRNAs in cardiovascular diseases. Circ. J. 2014, 78, 567-575.
36. Briasoulis, A.; Tousoulis, D.; Vogiatzi, G.; Siasos, G.; Papageorgiou, N.; Oikonomou, E.; Genimata, V.; Konsola, T.; Stefanadis, C. MicroRNAs: Biomarkers for cardiovascular disease in patients with diabetes mellitus. Curr. Top. Med. Chem. 2013, 13, 1533-1539.
37. Shantikumar, S.; Caporali, A.; Emanueli, C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc. Res. 2012, 93, 583-593.
38. Ruiz, M.A.; Chakrabarti, S. MicroRNAs: The underlying mediators of pathogenetic processes in vascular complications of diabetes. Can. J. Diabetes 2013, 37, 339-344.
39. Vickers, K.C.; Rye, K.A.; Tabet, F. MicroRNAs in the onset and development of cardiovascular disease. Clin. Sci. 2014, 126, 183-194.
40. Jaguszewski, M.; Osipova, J.; Ghadri, J.R.; Napp, L.C.; Widera, C.; Franke, J.; Fijalkowski, M.; Nowak, R.; Fijalkowska, M.; Volkmann, I., et al. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. Eur. Heart J. 2014, 35, 999-1006.
41. Gupta, M.K.; Halley, C.; Duan, Z.H.; Lappe, J.; Vite RNAJ.; Jana, S.; Augoff, K.; Mohan, M.L.; Vasudevan, N.T.; Na, J., et al. MiRNA-548c: A specific signature in circulating pbmcs from dilated cardiomyopathy patients. J. Mol. Cell Cardiol. 2013, 62, 131-141.
42. Huang, Z.P.; Chen, J.; Seok, H.Y.; Zhang, Z.; Kataoka, M.; Hu, X.; Wang, D.Z. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ. Res. 2013, 112, 1234-1243.
43. Bang, C.; Batkai, S.; Dangwal, S.; Gupta, S.K.; Foinquinos, A.; Holzmann, A.; Just, A.; Remke, J.; Zimmer, K.; Zeug, A., et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J. Clin. Invest. 2014, 124, 2136-2146.
44. Reaven, G.M. Multiple chd risk factors in type 2 diabetes: Beyond hyperglycaemia. Diabetes Obes. Metab. 2002, 4, S13-S18.
45. Kuwahata, S.; Fujita, S.; Orihara, K.; Hamasaki, S.; Oba, R.; Hirai, H.; Nagata, K.; Ishida, S.; Kataoka, T.; Oketani, N., et al. High expression level of toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease. Atherosclerosis 2010, 209, 248-254.
46. Weiner, S.D.; Ahmed, H.N.; Jin, Z.; Cushman, M.; Herrington, D.M.; Nelson, J.C.; di Tullio, M.R.; Homma, S. Systemic inflammation and brachial artery endothelial function in the multi-ethnic study of atherosclerosis (mesa). Heart 2014, doi:10.1136/heartjnl-2013-304893.
47. Xiao, L.; Liu, Y.; Wang, N. New paradigms in inflammatory signaling in vascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2014, 306, H317-H325.
48. Wang, L.; Yang, Y.; Hong, B. Advances in the role of microRNAs in lipid metabolism-related anti-atherosclerotic drug discovery. Expert Opin. Drug Discov. 2013, 8, 977-990.
49. Zampetaki, A.; Dudek, K.; Mayr, M. Oxidative stress in atherosclerosis: The role of microRNAs in arterial remodeling. Free Radic. Biol. Med. 2013, 64, 69-77.
50. Magenta, A.; Greco, S.; Gaetano, C.; Martelli, F. Oxidative stress and microRNAs in vascular diseases. Int. J. Mol. Sci. 2013, 14, 17319-17346.
51. Zernecke, A. MicroRNAs in the regulation of immune cell functions—Implications for atherosclerotic vascular disease. Thromb. Haemost. 2012, 107, 626-633.
52. Busch, M.; Zernecke, A. MicroRNAs in the regulation of dendritic cell functions in inflammation and atherosclerosis. J. Mol. Med. 2012, 90, 877-885.
53. Raitoharju, E.; Oksala, N.; Lehtimaki, T. MicroRNAs in the atherosclerotic plaque. Clin. Chem. 2013, 59, 1708-1721.
54. Siasos, G.; Kollia, C.; Tsigkou, V.; Basdra, E.K.; Lymperi, M.; Oikonomou, E.; Kokkou, E.; Korompelis, P.; Papavassiliou, A.G. MicroRNAs: Novel diagnostic and prognostic biomarkers in atherosclerosis. Curr. Top. Med. Chem. 2013, 13, 1503-1517.
55. Leung, A.; Natarajan, R. Noncoding RNAs in vascular disease. Curr. Opin. Cardiol. 2014, 29, 199-206.
56. Menghini, R.; Stohr, R.; Federici, M. MicroRNAs in vascular aging and atherosclerosis. Ageing Res. Rev. 2014, doi:10.1016/j.arr.2014.03.005.
57. Weber, M.; Kim, S.; Patterson, N.; Rooney, K.; Searles, C.D. MiRNA-155 targets myosin light chain kinase and modulates actin cytoskeleton organization in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2014, 306, H1192-H1203.
58. Tian, F.J.; An, L.N.; Wang, G.K.; Zhu, J.Q.; Li, Q.; Zhang, Y.Y.; Zeng, A.; Zou, J.; Zhu, R.F.; Han, X.S., et al. Elevated microRNA-155 promotes foam cell formation by targeting hbp1 in atherogenesis. Cardiovasc. Res. 2014, doi:10.1093/cvr/cvu070.
59. Hu, Y.W.; Hu, Y.R.; Zhao, J.Y.; Li, S.F.; Ma, X.; Wu, S.G.; Lu, J.B.; Qiu, Y.R.; Sha, Y.H.; Wang, Y.C., et al. An agomir of mir-144-3p accelerates plaque formation through impairing reverse cholesterol transport and promoting pro-inflammatory cytokine production. PLoS One 2014, 9, e94997.
60. Yang, Q.; Yang, K.; Li, A. MicroRNA21 protects against ischemiareperfusion and hypoxiareperfusioninduced cardiocyte apoptosis via the phosphatase and tensin homolog?aktdependent mechanism. Mol. Med. Rep. 2014, 9, 2213-2220.
61. Pan, Y.; Liang, H.; Liu, H.; Li, D.; Chen, X.; Li, L.; Zhang, C.Y.; Zen, K. Platelet-secreted microRNA-223 promotes endothelial cell apoptosis induced by advanced glycation end products via targeting the insulin-like growth factor 1 receptor. J. Immunol. 2014, 192, 437-446.
62. Vinod, M.; Chennamsetty, I.; Colin, S.; Belloy, L.; de Paoli, F.; Schaider, H.; Graier, W.F.; Frank, S.; Kratky, D.; Staels, B., et al. Mir-206 controls lxralpha expression and promotes lxr-mediated cholesterol efflux in macrophages. Biochim. Biophys. Acta 2014, 1841, 827-835.
63. Ying, C.; Sui-Xin, L.; Kang-Ling, X.; Wen-Liang, Z.; Lei, D.; Yuan, L.; Fan, Z.; Chen, Z. MicroRNA-492 reverses high glucose-induced insulin resistance in huvec cells through targeting resistin. Mol. Cell. Biochem. 2014, 391, 117-125.
64. Stephenson, J.; Fuller, J.H. Microvascular and acute complications in iddm patients: The eurodiab iddm complications study. Diabetologia 1994, 37, 278-285.
65. Scanlon, P.H.; Aldington, S.J.; Stratton, I.M. Epidemiological issues in diabetic retinopathy. Middle East Afr. J. Ophthalmol. 2013, 20, 293-300.
66. Papavasileiou, E.; Dereklis, D.; Oikonomidis, P.; Grixti, A.; Vineeth Kumar, B.; Prasad, S. An effective programme to systematic diabetic retinopathy screening in order to reduce diabetic retinopathy blindness. Hellenic J. Nucl. Med. 2014, 17, S30-S34.
67. Kato, M.; Castro, N.E.; Natarajan, R. MicroRNAs: Potential mediators and biomarkers of diabetic complications. Free Radic. Biol. Med. 2013, 64, 85-94.
68. Xiong, F.; Du, X.; Hu, J.; Li, T.; Du, S.; Wu, Q. Altered retinal microRNA expression profiles in early diabetic retinopathy: An in silico analysis. Curr. Eye Res. 2014, 39, 720-729.
69. Kovacs, B.; Lumayag, S.; Cowan, C.; Xu, S. MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest. Ophthalmol. Vis. Sci. 2011, 52, 4402-4409.
70. Hou, Q.; Tang, J.; Wang, Z.; Wang, C.; Chen, X.; Hou, L.; Dong, X.D.; Tu, L. Inhibitory effect of microRNA-34a on retinal pigment epithelial cell proliferation and migration. Invest. Ophthalmol. Vis. Sci. 2013, 54, 6481-6488.
71. Jindal, V. Neurodegeneration as a primary change and role of neuroprotection in diabetic retinopathy. Mol. Neurobiol. 2014, doi:10.1007/s12035-014-8732-7.
72. Li, X.; Zhang, M.; Zhou, H. The morphological features and mitochondrial oxidative stress mechanism of the retinal neurons apoptosis in early diabetic rats. J. Diabetes Res. 2014, 2014, 678123.
73. Silva, V.A.; Polesskaya, A.; Sousa, T.A.; Correa, V.M.; Andre, N.D.; Reis, R.I.; Kettelhut, I.C.; Harel-Bellan, A.; de Lucca, F.L. Expression and cellular localization of microRNA-29b and rax, an activator of the RNA-dependent protein kinase (pkr), in the retina of streptozotocin-induced diabetic rats. Mol. Vis. 2011, 17, 2228-2240.
74. Chen, X.; Ye, S.; Xiao, W.; Luo, L.; Liu, Y. Differentially expressed microRNAs in tgfbeta2-induced epithelial-mesenchymal transition in retinal pigment epithelium cells. Int. J. Mol. Med. 2014, 33, 1195-1200.
75. Cheng, H.C.; Ho, T.C.; Chen, S.L.; Lai, H.Y.; Hong, K.F.; Tsao, Y.P. Troglitazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells. Mol. Vis. 2008, 14, 95-104.
76. Mortuza, R.; Feng, B.; Chakrabarti, S. Mir-195 regulates sirt1-mediated changes in diabetic retinopathy. Diabetologia 2014, 57, 1037-1046.
77. Bento, C.F.; Fernandes, R.; Matafome, P.; Sena, C.; Seica, R.; Pereira, P. Methylglyoxal-induced imbalance in the ratio of vascular endothelial growth factor to angiopoietin 2 secreted by retinal pigment epithelial cells leads to endothelial dysfunction. Exp. Physiol. 2010, 95, 955-970.
78. Ling, S.; Birnbaum, Y.; Nanhwan, M.K.; Thomas, B.; Bajaj, M.; Ye, Y. MicroRNA-dependent cross-talk between vegf and hif1alpha in the diabetic retina. Cell. Signal. 2013, 25, 2840-2847.
79. Ye, P.; Liu, J.; He, F.; Xu, W.; Yao, K. Hypoxia-induced deregulation of mir-126 and its regulative effect on vegf and mmp-9 expression. Int. J. Med. Sci. 2014, 11, 17-23.
80. Murray, A.R.; Chen, Q.; Takahashi, Y.; Zhou, K.K.; Park, K.; Ma, J.X. MicroRNA-200b downregulates oxidation resistance 1 (oxr1) expression in the retina of type 1 diabetes model. Invest. Ophthalmol. Vis. Sci. 2013, 54, 1689-1697.
81. McArthur, K.; Feng, B.; Wu, Y.; Chen, S.; Chakrabarti, S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 2011, 60, 1314-1323.
82. Gohda, T.; Mima, A.; Moon, J.Y.; Kanasaki, K. Combat diabetic nephropathy: From pathogenesis to treatment. J. Diabetes Res. 2014, 2014, 207140.
83. Bichu, P.; Nistala, R.; Khan, A.; Sowers, J.R.; Whaley-Connell, A. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: Results from the amadeo study. Vasc. Health Risk Manag. 2009, 5, 129-140.
84. Collins, A.J.; Foley, R.N.; Herzog, C.; Chavers, B.; Gilbertson, D.; Ishani, A.; Kasiske, B.; Liu, J.; Mau, L.W.; McBean, M., et al. United states renal data system 2008 annual data report. Am. J. Kidney Dis. 2009, 53, S1-S374.
85. Alvarez, M.L.; Distefano, J.K. The role of non-coding RNAs in diabetic nephropathy: Potential applications as biomarkers for disease development and progression. Diabetes Res. Clin. Pract. 2013, 99, 1-11.
86. Macisaac, R.J.; Ekinci, E.I.; Jerums, G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am. J. Kidney Dis. 2014, 63, S39-S62.
87. Jalal, D.I.; Rivard, C.J.; Johnson, R.J.; Maahs, D.M.; McFann, K.; Rewers, M.; Snell-Bergeon, J.K. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: Findings from the coronary artery calcification in type 1 diabetes study. Nephrol. Dial. Transplant. 2010, 25, 1865-1869.
88. Acosta, J.B.; del Barco, D.G.; Vera, D.C.; Savigne, W.; Lopez-Saura, P.; Guillen Nieto, G.; Schultz, G.S. The pro-inflammatory environment in recalcitrant diabetic foot wounds. Int. Wound J. 2008, 5, 530-539.
89. Lin, C.L.; Hsu, Y.C.; Lee, P.H.; Lei, C.C.; Wang, J.Y.; Huang, Y.T.; Wang, S.Y.; Wang, F.S. Cannabinoid receptor 1 disturbance of PPAR_2 augments hyperglycemia induction of mesangial inflammation and fibrosis in renal glomeruli. J. Mol. Med. 2014, 92, 779-792.
90. Bocci, V.; Zanardi, I.; Huijberts, M.S.; Travagli, V. An integrated medical treatment for type-2 diabetes. Diabetes Metab. Syndr. 2014, 8, 57-61.
91. Tan, S.M.; Sharma, A.; Stefanovic, N.; Yuen, D.Y.; Karagiannis, T.C.; Meyer, C.; Ward, K.W.; Cooper, M.E.; de Haan, J.B. A derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner, lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. Diabetes 2014, 63, 3091-3103.
92. Acikgoz, Y.; Can, B.; Bek, K.; Acikgoz, A.; Ozkaya, O.; Genc, G.; Sarikaya, S. The effect of simvastatin and erythropoietin on renal fibrosis in rats with unilateral ureteral obstruction. Renal Fail. 2014, 36, 252-257.
93. Brennan, E.; McEvoy, C.; Sadlier, D.; Godson, C.; Martin, F. The genetics of diabetic nephropathy. Genes (Basel) 2013, 4, 596-619.
94. McClelland, A.; Hagiwara, S.; Kantharidis, P. Where are we in diabetic nephropathy: MicroRNAs and biomarkers? Curr. Opin. Nephrol. Hypertens. 2014, 23, 80-86.
95. Khella, H.W.; Bakhet, M.; Lichner, Z.; Romaschin, A.D.; Jewett, M.A.; Yousef, G.M. MicroRNAs in kidney disease: An emerging understanding. Am. J. Kidney Dis. 2013, 61, 798-808.
96. Chandrasekaran, K.; Karolina, D.S.; Sepramaniam, S.; Armugam, A.; Wintour, E.M.; Bertram, J.F.; Jeyaseelan, K. Role of microRNAs in kidney homeostasis and disease. Kidney Int. 2012, 81, 617-627.
97. Srivastava, S.P.; Koya, D.; Kanasaki, K. MicroRNAs in kidney fibrosis and diabetic nephropathy: Roles on emt and endmt. Biomed. Res. Int. 2013, 2013, 125469.
98. Kato, M.; Park, J.T.; Natarajan, R. MicroRNAs and the glomerulus. Exp. Cell Res. 2012, 318, 993-1000.
99. Liang, M.; Liu, Y.; Mladinov, D.; Cowley, A.W., Jr.; Trivedi, H.; Fang, Y.; Xu, X.; Ding, X.; Tian, Z. MicroRNA: A new frontier in kidney and blood pressure research. Am. J. Physiol. Renal. Physiol. 2009, 297, F553-F558.
100. Hagiwara, S.; McClelland, A.; Kantharidis, P. MicroRNA in diabetic nephropathy: Renin angiotensin, age/rage, and oxidative stress pathway. J. Diabetes Res. 2013, 2013, 173783.
101. Lan, H.Y. Transforming growth factor-beta/smad signalling in diabetic nephropathy. Clin. Exp. Pharmacol. Physiol. 2012, 39, 731-738.
102. Zhang, L.; He, S.; Guo, S.; Xie, W.; Xin, R.; Yu, H.; Yang, F.; Qiu, J.; Zhang, D.; Zhou, S., et al. Down-regulation of mir-34a alleviates mesangial proliferation in vitro and glomerular hypertrophy in early diabetic nephropathy mice by targeting gas1. J. Diabetes Complicat. 2014, 28, 259-264.
103. Lin, C.L.; Lee, P.H.; Hsu, Y.C.; Lei, C.C.; Ko, J.Y.; Chuang, P.C.; Huang, Y.T.; Wang, S.Y.; Wu, S.L.; Chen, Y.S., et al. MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction. J. Am. Soc. Nephrol. 2014, doi:10.1681/ASN.2013050527.
104. DiStefano, J.K.; Taila, M.; Alvarez, M.L. Emerging roles for miRNAs in the development, diagnosis, and treatment of diabetic nephropathy. Curr. Diab. Rep. 2013, 13, 582-591.
105. Cachia, M.J.; Peakman, M.; Zanone, M.; Watkins, P.J.; Vergani, D. Reproducibility and persistence of neural and adrenal autoantibodies in diabetic autonomic neuropathy. Diabetic Med. 1997, 14, 461-465.
106. Kostev, K.; Jockwig, A.; Hallwachs, A.; Rathmann, W. Prevalence and risk factors of neuropathy in newly diagnosed type 2 diabetes in primary care practices: A retrospective database analysis in germany and uk. Prim. Care Diabetes 2014, 8, 250-255.
107. Callaghan, B.C.; Cheng, H.T.; Stables, C.L.; Smith, A.L.; Feldman, E.L. Diabetic neuropathy: Clinical manifestations and current treatments. Lancet Neurol. 2012, 11, 521-534.
108. Tesfaye, S.; Boulton, A.J.; Dyck, P.J.; Freeman, R.; Horowitz, M.; Kempler, P.; Lauria, G.; Malik, R.A.; Spallone, V.; Vinik, A., et al. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010, 33, 2285-2293.
109. Tellechea, A.; Kafanas, A.; Leal, E.C.; Tecilazich, F.; Kuchibhotla, S.; Auster, M.E.; Kontoes, I.; Paolino, J.; Carvalho, E.; Nabzdyk, L.P., et al. Increased skin inflammation and blood vessel density in human and experimental diabetes. Int. J. Low Extrem. Wounds 2013, 12, 4-11.
110. Deli, G.; Bosnyak, E.; Pusch, G.; Komoly, S.; Feher, G. Diabetic neuropathies: Diagnosis and management. Neuroendocrinology 2013, 98, 267-280.
111. Bansal, V.; Kalita, J.; Misra, U.K. Diabetic neuropathy. Postgrad. Med. J. 2006, 82, 95-100.
112. Malik, R.; Veves, A.; Tesfaye, S.; Smith, G.; Cameron, N.; Zochodne, D.; Lauria, G.; The Toronto Consensus Panel on Diabetic Neuropathy. Small fiber neuropathy: Role in the diagnosis of diabetic sensorimotor polyneuropathy. Diabetes Metab. Res. Rev. 2011, doi:10.1002/dmrr.1222.
113. Daemen, M.A.; Kurvers, H.A.; Kitslaar, P.J.; Slaaf, D.W.; Bullens, P.H.; van den Wildenberg, F.A. Neurogenic inflammation in an animal model of neuropathic pain. Neurol. Res. 1998, 20, 41-45.
114. Pradhan Nabzdyk, L.; Kuchibhotla, S.; Guthrie, P.; Chun, M.; Auster, M.E.; Nabzdyk, C.; Deso, S.; Andersen, N.; Gnardellis, C.; LoGerfo, F.W., et al. Expression of neuropeptides and cytokines in a rabbit model of diabetic neuroischemic wound healing. J. Vasc. Surg. 2013, 58, 766-775.
115. Moura, L.I.; Dias, A.M.; Leal, E.C.; Carvalho, L.; de Sousa, H.C.; Carvalho, E. Chitosan-based dressings loaded with neurotensin—An efficient strategy to improve early diabetic wound healing. Acta Biomater. 2014, 10, 843-857.
116. Bali, K.K.; Hackenberg, M.; Lubin, A.; Kuner, R.; Devor, M. Sources of individual variability: MiRNAs that predispose to neuropathic pain identified using genome-wide sequencing. Mol. Pain 2014, 10, 22.
117. Li, H.; Huang, Y.; Ma, C.; Yu, X.; Zhang, Z.; Shen, L. Mir-203 involves in neuropathic pain development and represses rap1a expression in nerve growth factor differentiated neuronal PC12 cells. Clin. J. Pain 2014, doi:10.1097/AJP.0000000000000070.
118. Chen, H.P.; Zhou, W.; Kang, L.M.; Yan, H.; Zhang, L.; Xu, B.H.; Cai, W.H. Intrathecal mir-96 inhibits nav1.3 expression and alleviates neuropathic pain in rat following chronic construction injury. Neurochem. Res. 2014, 39, 76-83.
119. Sakai, A.; Saitow, F.; Miyake, N.; Miyake, K.; Shimada, T.; Suzuki, H. Mir-7a alleviates the maintenance of neuropathic pain through regulation of neuronal excitability. Brain 2013, 136, 2738-2750.
120. Ciccacci, C.; Morganti, R.; di Fusco, D.; D’Amato, C.; Cacciotti, L.; Greco, C.; Rufini, S.; Novelli, G.; Sangiuolo, F.; Marfia, G.A., et al. Common polymorphisms in MIR146a, MIR128a and MIR27a genes contribute to neuropathy susceptibility in type 2 diabetes. Acta Diabetol. 2014, 51, 673-671.
121. Zhou, S.; Gao, R.; Hu, W.; Qian, T.; Wang, N.; Ding, G.; Ding, F.; Yu, B.; Gu, X. Mir-9 inhibits schwann cell migration by targeting cthrc1 following sciatic nerve injury. J. Cell Sci. 2014, 127, 967-976.
122. Gupta, S.K.; Singh, S.K. Diabetic foot: A continuing challenge. Adv. Exp. Med. Biol. 2012, 771, 123-138.
123. Lu, M.H.; Hu, C.J.; Chen, L.; Peng, X.; Chen, J.; Hu, J.Y.; Teng, M.; Liang, G.P. Mir-27b represses migration of mouse mscs to burned margins and prolongs wound repair through silencing SDF-1a. PLoS ONE 2013, 8, e68972.
124. Wang, J.M.; Tao, J.; Chen, D.D.; Cai, J.J.; Irani, K.; Wang, Q.; Yuan, H.; Chen, A.F. MicroRNA mir-27b rescues bone marrow-derived angiogenic cell function and accelerates wound healing in type 2 diabetes mellitus. Arterioscler Thromb Vasc. Biol. 2014, 34, 99-109.
125. Meisgen, F.; Xu Landen, N.; Bouez, C.; Zuccolo, M.; Gueniche, A.; Stahle, M.; Sonkoly, E.; Breton, L.; Pivarcsi, A. Activation of toll-like receptors alters the microRNA expression profile of keratinocytes. Exp. Dermatol. 2014, 23, 281-283.
126. Ning, M.S.; Andl, T. Control by a hairs breadth: The role of microRNAs in the skin. Cell Mol. Life Sci. 2013, 70, 1149-1169.
127. Schneider, M.R. MicroRNAs as novel players in skin development, homeostasis and disease. Br. J. Dermatol. 2012, 166, 22-28.
128. Moura, L.I.; Cruz, M.T.; Carvalho, E. The effect of neurotensin in human keratinocytes—Implication on impaired wound healing in diabetes. Exp. Biol. Med. (Maywood) 2014, 239, 6-12.
129. Moura, L.I.; Silva, L.; Leal, E.C.; Tellechea, A.; Cruz, M.T.; Carvalho, E. Neurotensin modulates the migratory and inflammatory response of macrophages under hyperglycemic conditions. Biomed. Res. Int. 2013, 2013, 941764.
130. Rodero, M.P.; Khosrotehrani, K. Skin wound healing modulation by macrophages. Int. J. Clin. Exp. Pathol. 2010, 3, 643-653.
131. Rot, A.; von Andrian, U.H. Chemokines in innate and adaptive host defense: Basic chemokinese grammar for immune cells. Ann. Rev. Immunol. 2004, 22, 891-928.
132. Le, Y.; Yang, Y.; Cui, Y.; Yazawa, H.; Gong, W.; Qiu, C.; Wang, J.M. Receptors for chemotactic formyl peptides as pharmacological targets. Int. Immunopharmacol. 2002, 2, 1-13.
133. Zhai, Y.; Zhong, Z.; Chen, C.Y.; Xia, Z.; Song, L.; Blackburn, M.R.; Shyu, A.B. Coordinated changes in mRNA turnover, translation, and RNA processing bodies in bronchial epithelial cells following inflammatory stimulation. Mol. Cell Biol. 2008, 28, 7414-7426.
134. Nakamachi, Y.; Kawano, S.; Takenokuchi, M.; Nishimura, K.; Sakai, Y.; Chin, T.; Saura, R.; Kurosaka, M.; Kumagai, S. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheumatol. 2009, 60, 1294-1304.
135. Dorhoi, A.; Iannaccone, M.; Farinacci, M.; Fae, K.C.; Schreiber, J.; Moura-Alves, P.; Nouailles, G.; Mollenkopf, H.J.; Oberbeck-Muller, D.; Jorg, S., et al. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J. Clin. Invest. 2013, 123, 4836-4848.
136. Pradhan, L.; Cai, X.; Wu, S.; Andersen, N.D.; Martin, M.; Malek, J.; Guthrie, P.; Veves, A.; Logerfo, F.W. Gene expression of pro-inflammatory cytokines and neuropeptides in diabetic wound healing. J. Surg. Res. 2011, 167, 336-342.
137. Galkowska, H.; Wojewodzka, U.; Olszewski, W.L. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regener. 2006, 14, 558-565.
138. Min, M.; Peng, L.; Yang, Y.; Guo, M.; Wang, W.; Sun, G. MicroRNA-155 is involved in the pathogenesis of ulcerative colitis by targeting FOXO3a. Inflammatory Bowel Dis. 2014, 20, 652-659.
139. Fabbri, E.; Borgatti, M.; Montagner, G.; Bianchi, N.; Finotti, A.; Lampronti, I.; Bezzerri, V.; Dechecchi, M.C.; Cabrini, G.; Gambari, R. Expression of microRNA-93 and Interleukin-8 during pseudomonas aeruginosa mediated induction of pro-inflammatory responses. Am. J. Respir. Cell Mol. Biol. 2014, 50, 1144-1155.
140. Zykova, S.N.; Jenssen, T.G.; Berdal, M.; Olsen, R.; Myklebust, R.; Seljelid, R. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 2000, 49, 1451-1458.
141. Harris, T.A.; Yamakuchi, M.; Ferlito, M.; Mendell, J.T.; Lowenstein, C.J. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc. Natl. Acad. Sci. USA 2008, 105, 1516-1521.
142. Ortega, F.J.; Mercader, J.M.; Moreno-Navarrete, J.M.; Rovira, O.; Guerra, E.; Esteve, E.; Xifra, G.; Martinez, C.; Ricart, W.; Rieusset, J., et al. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care 2014, 67, 51375-51383.
143. Zhang, T.; Lv, C.; Li, L.; Chen, S.; Liu, S.; Wang, C.; Su, B. Plasma mir-126 is a potential biomarker for early prediction of type 2 diabetes mellitus in susceptible individuals. Biomed. Res. Int. 2013, 2013, 761617.
144. Dianzani, U.; Funaro, A.; DiFranco, D.; Garbarino, G.; Bragardo, M.; Redoglia, V.; Buonfiglio, D.; de Monte, L.B.; Pileri, A.; Malavasi, F. Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule. J. Immunol. 1994, 153, 952-959.
145. Jude, J.A.; Dileepan, M.; Subramanian, S.; Solway, J.; Panettieri, R.A., Jr.; Walseth, T.F.; Kannan, M.S. Mir-140-3p regulation of tnf-alpha-induced cd38 expression in human airway smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2012, 303, L460-L468.
146. Collares, C.V.; Evangelista, A.F.; Xavier, D.J.; Rassi, D.M.; Arns, T.; Foss-Freitas, M.C.; Foss, M.C.; Puthier, D.; Sakamoto-Hojo, E.T.; Passos, G.A., et al. Identifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients. BMC Res. Notes 2013, 6, 491.
147. Shanmugam, N.; Reddy, M.A.; Natarajan, R. Distinct roles of heterogeneous nuclear ribonuclear protein k and microRNA-16 in cyclooxygenase-2 RNA stability induced by s100b, a ligand of the receptor for advanced glycation end products. J. Biol. Chem. 2008, 283, 36221-36233.
148. Mokhtar, S.S.; Vanhoutte, P.M.; Leung, S.W.S.; Yusof, M.I.; Sulaiman, W.A.W.; Saad, A.Z.M.; Suppian, R.; Rasoo, A.H.G. Reduced expression of prostacyclin synthase and nitric oxide synthase in subcutaneous arteries of type 2 diabetic patients. Tohoku J. Exp. Med. 2013, 231, 217-222.
149. Matouskova, P.; Bartikova, H.; Bousova, I.; Hanusova, V.; Szotakova, B.; Skalova, L. Reference genes for real-time PCR quantification of messenger RNAs and microRNAs in mouse model of obesity. PLoS ONE 2014, 9, e86033.
150. Ortega, F.J.; Mercader, J.M.; Catalan, V.; Moreno-Navarrete, J.M.; Pueyo, N.; Sabater, M.; Gomez-Ambrosi, J.; Anglada, R.; Fernandez-Formoso, J.A.; Ricart, W., et al. Targeting the circulating microRNA signature of obesity. Clin. Chem. 2013, 59, 781-792.
151. Nesca, V.; Guay, C.; Jacovetti, C.; Menoud, V.; Peyot, M.L.; Laybutt, D.R.; Prentki, M.; Regazzi, R. Identification of particular groups of microRNAs that positively or negatively impact on beta cell function in obese models of type 2 diabetes. Diabetologia 2013, 56, 2203-2212.
152. Primo, M.N.; Bak, R.O.; Schibler, B.; Mikkelsen, J.G. Regulation of pro-inflammatory cytokines TNF_and IL24 by microRNA-203 in primary keratinocytes. Cytokine 2012, 60, 741-748.
153. Mi, Q.; Riviere, B.; Clermont, G.; Steed, D.L.; Vodovotz, Y. Agent-based model of inflammation and wound healing: Insights into diabetic foot ulcer pathology and the role of transforming growth factor-beta1. Wound Repair Regener. 2007, 15, 671-682.
154. Ennis, W.J.; Sui, A.; Bartholomew, A. Stem cells and healing: Impact on inflammation. Adv. Wound Care (New Rochelle) 2013, 2, 369-378.
155. Xu, J.; Wu, W.; Zhang, L.; Dorset-Martin, W.; Morris, M.W.; Mitchell, M.E.; Liechty, K.W. The role of microRNA-146a in the pathogenesis of the diabetic wound-healing impairment: Correction with mesenchymal stem cell treatment. Diabetes 2012, 61, 2906-2912.
156. Dickinson, S.; Hancock, D.P.; Petocz, P.; Ceriello, A.; Brand-Miller, J. High-glycemic index carbohydrate increases nuclear factor-_b activation in mononuclear cells of young, lean healthy subjects. Am. J. Clin. Nutr. 2008, 87, 1188-1193.
157. Stegenga, M.E.; van der Crabben, S.N.; Dessing, M.C.; Pater, J.M.; van den Pangaart, P.S.; de Vos, A.F.; Tanck, M.W.; Roos, D.; Sauerwein, H.P.; van der Poll, T. Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production and neutrophil function in humans. Diabetic Med. 2008, 25, 157-164.
158. Bogdanski, P.; Pupek-Musialik, D.; Dytfeld, J.; Jagodzinski, P.P.; Jablecka, A.; Kujawa, A.; Musialik, K. Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus. Int. J. Clin. Pharmacol. Ther. 2007, 45, 563-567.
159. Balasubramanyam, M.; Aravind, S.; Gokulakrishnan, K.; Prabu, P.; Sathishkumar, C.; Ranjani, H.; Mohan, V. Impaired MIR-146a expression links subclinical inflammation and insulin resistance in type 2 diabetes. Mol. Cell Biochem. 2011, 351, 197-205.
160. Tellechea, A.; Leal, E.; Veves, A.; Cravalho, E. Inflammatory and angiogenic abnormalities in diabetic wound healing: Role of neuropeptides and therapeutic perspectives. Open Circ. Vasc. J. 2010, 3, 43-55.
161. Pottier, N.; Maurin, T.; Chevalier, B.; Puissegur, M.P.; Lebrigand, K.; Robbe-Sermesant, K.; Bertero, T.; Lino Cardenas, C.L.; Courcot, E.; Rios, G., et al. Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: Implication in epithelial-mesenchymal interactions. PLoS ONE 2009, 4, e6718.
162. Corral-Fernandez, N.E.; Salgado-Bustamante, M.; Martinez-Leija, M.E.; Cortez-Espinosa, N.; Garcia-Hernandez, M.H.; Reynaga-Hernandez, E.; Quezada-Calvillo, R.; Portales-Perez, D.P. Dysregulated MIR-155 expression in peripheral blood mononuclear cells from patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 2013, 121, 347-353.
163. Kishore, R.; Verma, S.K.; Mackie, A.R.; Vaughan, E.E.; Abramova, T.V.; Aiko, I.; Krishnamurthy, P. Bone marrow progenitor cell therapy-mediated paracrine regulation of cardiac miRNA-155 modulates fibrotic response in diabetic hearts. PLoS One 2013, 8, e60161.
164. Madhyastha, R.; Madhyastha, H.; Nakajima, Y.; Omura, S.; Maruyama, M. MicroRNA signature in diabetic wound healing: Promotive role of MIR-21 in fibroblast migration. Int. Wound J. 2012, 9, 355-361.
165. Delavary, B.M.; van der Veer, W.M.; van Egmond, M.; Niessen, F.B.; Beelen, R.H. Macrophages in skin injury and repair. Immunobiology 2011, 216, 753-762.
166. Brancato, S.K.; Albina, J.E. Wound macrophages as key regulators of repair: Origin, phenotype, and function. Am. J. Pathol. 2011, 178, 19-25.
167. Meng, S.; Cao, J.T.; Zhang, B.; Zhou, Q.; Shen, C.X.; Wang, C.Q. Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene spred-1. J. Mol. Cell Cardiol. 2012, 53, 64-72.
168. Meng, S.; Cao, J.; Zhang, X.; Fan, Y.; Fang, L.; Wang, C.; Lv, Z.; Fu, D.; Li, Y. Downregulation of microRNA-130a contributes to endothelial progenitor cell dysfunction in diabetic patients via its target Runx3. PLoS ONE 2013, 8, e68611.
169. Wang, C.H.; Lee, D.Y.; Deng, Z.; Jeyapalan, Z.; Lee, S.C.; Kahai, S.; Lu, W.Y.; Zhang, Y.; Yang, B.B. MicroRNA mir-328 regulates zonation morphogenesis by targeting CD44 expression. PLoS ONE 2008, 3, e2420.
170. Collares, C.; Evangelista, A.; Xavier, D.; Macedo, C.; Rassi, D.; Foss-Freitas, M.; Foss, M.; Sakamoto-Hojo, E.; Passos, G.; Donadi, E. Meta-analysis of differentially expressed microRNAs in type 1, type 2 and gestational diabetes mellitus. Endocrine Abstracts 2012, 29, OC17.6.
171. Caporali, A.; Emanueli, C. MicroRNA-503 and the extended microRNA-16 family in angiogenesis. Trends Cardiovasc. Med. 2011, 21, 162-166.
172. Jordan, S.D.; Kruger, M.; Willmes, D.M.; Redemann, N.; Wunderlich, F.T.; Bronneke, H.S.; Merkwirth, C.; Kashkar, H.; Olkkonen, V.M.; Bottger, T., et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated akt activation and impairs glucose metabolism. Nat. Cell Biol. 2011, 13, 434-446.
173. Blumensatt, M.; Greulich, S.; de Wiza, D.H.; Mueller, H.; Maxhera, B.; Rabelink, M.J.; Hoeben, R.C.; Akhyari, P.; Al-Hasani, H.; Ruige, J.B., et al. Activin a impairs insulin action in cardiomyocytes via up-regulation of mir-143. Cardiovasc. Res. 2013, 100, 201-210.
174. Kohlstedt, K.; Trouvain, C.; Boettger, T.; Shi, L.; Fisslthaler, B.; Fleming, I. Amp-activated protein kinase regulates endothelial cell angiotensin-converting enzyme expression via p53 and the post-transcriptional regulation of microRNA-143/145. Circ. Res. 2013, 112, 1150-1158.
175. Wang, S.; Aurora, A.B.; Johnson, B.A.; Qi, X.; McAnally, J.; Hill, J.A.; Richardson, J.A.; Bassel-Duby, R.; Olson, E.N. The endothelial-specific microRNA mir-126 governs vascular integrity and angiogenesis. Dev. Cell 2008, 15, 261-271.
176. Van Solingen, C.; Seghers, L.; Bijkerk, R.; Duijs, J.M.; Roeten, M.K.; van Oeveren-Rietdijk, A.M.; Baelde, H.J.; Monge, M.; Vos, J.B.; de Boer, H.C., et al. Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J. Cell Mol. Med. 2009, 13, 1577-1585.
177. Pastar, I.; Khan, A.A.; Stojadinovic, O.; Lebrun, E.A.; Medina, M.C.; Brem, H.; Kirsner, R.S.; Jimenez, J.J.; Leslie, C.; Tomic-Canic, M. Induction of specific microRNAs inhibits cutaneous wound healing. J. Biol. Chem. 2012, 287, 29324-29335.
178. Sundaram, G.M.; Common, J.E.; Gopal, F.E.; Srikanta, S.; Lakshman, K.; Lunny, D.P.; Lim, T.C.; Tanavde, V.; Lane, E.B.; Sampath, P. “See-saw” expression of microRNA-198 and FSTL1 from a single transcript in wound healing. Nature 2013, 495, 103-106.
179. Bertero, T.; Gastaldi, C.; Bourget-Ponzio, I.; Imbert, V.; Loubat, A.; Selva, E.; Busca, R.; Mari, B.; Hofman, P.; Barbry, P., et al. Mir-483-3p controls proliferation in wounded epithelial cells. FASEB J. 2011, 25, 3092-3105.
180. Viticchie, G.; Lena, A.M.; Cianfarani, F.; Odorisio, T.; Annicchiarico-Petruzzelli, M.; Melino, G.; Candi, E. MicroRNA-203 contributes to skin re-epithelialization. Cell Death Dis. 2012, 3, e435.
181. Ferland-McCollough, D.; Fernandez-Twinn, D.S.; Cannell, I.G.; David, H.; Warner, M.; Vaag, A.A.; Bork-Jensen, J.; Brons, C.; Gant, T.W.; Willis, A.E., et al. Programming of adipose tissue miR-483-3p and GDF-3 expression by maternal diet in type 2 diabetes. Cell Death Differ. 2012, 19, 1003-1012.
182. Hildebrand, J.; Rutze, M.; Walz, N.; Gallinat, S.; Wenck, H.; Deppert, W.; Grundhoff, A.; Knott, A. A comprehensive analysis of microRNA expression during human keratinocyte differentiation in vitro and in vivo. J. Invest. Dermatol. 2011, 131, 20-29.
183. Nielsen, L.B.; Wang, C.; Sorensen, K.; Bang-Berthelsen, C.H.; Hansen, L.; Andersen, M.L.; Hougaard, P.; Juul, A.; Zhang, C.Y.; Pociot, F., et al. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: Evidence that mir-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp. Diabetes Res. 2012, 2012, 896362.
184. Greco, S.; Fasanaro, P.; Castelvecchio, S.; D’Alessandra, Y.; Arcelli, D.; di Donato, M.; Malavazos, A.; Capogrossi, M.C.; Menicanti, L.; Martelli, F. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 2012, 61, 1633-1641.
185. Yang, X.; Wang, J.; Guo, S.L.; Fan, K.J.; Li, J.; Wang, Y.L.; Teng, Y.; Yang, X. Mir-21 promotes keratinocyte migration and re-epithelialization during wound healing. Int. J. Biol. Sci. 2011, 7, 685-690.
186. Wang, T.; Feng, Y.; Sun, H.; Zhang, L.; Hao, L.; Shi, C.; Wang, J.; Li, R.; Ran, X.; Su, Y., et al. Mir-21 regulates skin wound healing by targeting multiple aspects of the healing process. Am. J. Pathol. 2012, 181, 1911-1920.
187. Zeng, J.; Xiong, Y.; Li, G.; Liu, M.; He, T.; Tang, Y.; Chen, Y.; Cai, L.; Jiang, R.; Tao, J. Mir-21 is overexpressed in response to high glucose and protects endothelial cells from apoptosis. Exp. Clin. Endocrinol. Diabetes 2013, 121, 425-430.
188. Chakraborty, C.; George Priya Doss, C.; Bandyopadhyay, S. MiRNAs in insulin resistance and diabetes-associated pancreatic cancer: The “minute and miracle” molecule moving as a monitor in the “genomic galaxy”. Curr. Drug Targets 2013, 14, 1110-1117.
189. Jin, Y.; Tymen, S.D.; Chen, D.; Fang, Z.J.; Zhao, Y.; Dragas, D.; Dai, Y.; Marucha, P.T.; Zhou, X. MicroRNA-99 family targets AKT/mTOR signaling pathway in dermal wound healing. PLoS ONE 2013, 8, e64434.
190. Adam, L.; Zhong, M.; Choi, W.; Qi, W.; Nicoloso, M.; Arora, A.; Calin, G.; Wang, H.; Siefker-Radtke, A.; McConkey, D., et al. Mir-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 2009, 15, 5060-5072.
191. Reddy, M.A.; Jin, W.; Villeneuve, L.; Wang, M.; Lanting, L.; Todorov, I.; Kato, M.; Natarajan, R. Pro-inflammatory role of microRNA-200 in vascular smooth muscle cells from diabetic mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 721-729.
192. Costa, R.; Negrao, R.; Valente, I.; Castela, A.; Duarte, D.; Guardao, L.; Magalhaes, P.J.; Rodrigues, J.A.; Guimaraes, J.T.; Gomes, P., et al. Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing. J. Nat. Prod. 2013, 76, 2047-2053.
193. Darby, I.A.; Bisucci, T.; Hewitson, T.D.; MacLellan, D.G. Apoptosis is increased in a model of diabetes-impaired wound healing in genetically diabetic mice. Int. J. Biochem. Cell Biol. 1997, 29, 191-200.
194. Lin, A.; Hokugo, A.; Nishimura, I. Wound closure and wound management: A new therapeutic molecular target. Cell Adh. Migr. 2010, 4, 396-399.
195. Honda, N.; Jinnin, M.; Kajihara, I.; Makino, T.; Makino, K.; Masuguchi, S.; Fukushima, S.; Okamoto, Y.; Hasegawa, M.; Fujimoto, M., et al. TGF-_-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type i collagen expression in scleroderma dermal fibroblasts. J. Immunol. 2012, 188, 3323-3331.
196. Kashiyama, K.; Mitsutake, N.; Matsuse, M.; Ogi, T.; Saenko, V.A.; Ujifuku, K.; Utani, A.; Hirano, A.; Yamashita, S. Mir-196a downregulation increases the expression of type i and iii collagens in keloid fibroblasts. J. Invest. Dermatol. 2012, 132, 1597-1604.
197. Mori, M.; Nakagami, H.; Rodriguez-Araujo, G.; Nimura, K.; Kaneda, Y. Essential role for mir-196a in brown adipogenesis of white fat progenitor cells. PLoS Biol. 2012, 10, e1001314.
198. Moura, J.; da Silva, L.; Cruz, M.T.; Carvalho, E. Molecular and cellular mechanisms of bone morphogenetic proteins and activins in the skin: Potential benefits for wound healing. Arch. Dermatol. Res. 2013, 305, 557-569.
199. Munz, B.; Tretter, Y.P.; Hertel, M.; Engelhardt, F.; Alzheimer, C.; Werner, S. The roles of activins in repair processes of the skin and the brain. Mol. Cell Endocrinol. 2001, 180, 169-177.
200. Wu, H.; Wu, M.; Chen, Y.; Allan, C.A.; Phillips, D.J.; Hedger, M.P. Correlation between blood activin levels and clinical parameters of type 2 diabetes. Exp. Diabetes Res. 2012, 2012, 410579.
201. Mizuno, Y.; Tokuzawa, Y.; Ninomiya, Y.; Yagi, K.; Yatsuka-Kanesaki, Y.; Suda, T.; Fukuda, T.; Katagiri, T.; Kondoh, Y.; Amemiya, T., et al. Mir-210 promotes osteoblastic differentiation through inhibition of acvr1b. FEBS Lett 2009, 583, 2263-2268.
202. Liu, Y.; Taylor, N.E.; Lu, L.; Usa, K.; Cowley, A.W., Jr.; Ferreri, N.R.; Yeo, N.C.; Liang, M. Renal medullary microRNAs in dahl salt-sensitive rats: Mir-29b regulates several collagens and related genes. Hypertension 2010, 55, 974-982.
203. Cushing, L.; Kuang, P.P.; Qian, J.; Shao, F.; Wu, J.; Little, F.; Thannickal, V.J.; Cardoso, W.V.; Lu, J. Mir-29 is a major regulator of genes associated with pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2011, 45, 287-294.
204. Monaghan, M.; Browne, S.; Schenke-Layland, K.; Pandit, A. A collagen-based scaffold delivering exogenous microRNA-29b to modulate extracellular matrix remodeling. Mol. Ther. 2014, 22, 786-796.
205. Shilo, S.; Roy, S.; Khanna, S.; Sen, C.K. MicroRNA in cutaneous wound healing: A new paradigm. DNA Cell Biol. 2007, 26, 227-237.
206. Banerjee, J.; Sen, C.K. MicroRNAs in skin and wound healing. Methods Mol. Biol. 2013, 936, 343-356.
207. Sand, M.; Gambichler, T.; Sand, D.; Skrygan, M.; Altmeyer, P.; Bechara, F.G. MicroRNAs and the skin: Tiny players in the bodys largest organ. J. Dermatol. Sci. 2009, 53, 169-175.
208. Motameny, S.; Wolters, S.; Nurnberg, P.; Schumacher, B. Next generation sequencing of miRNAs—Strategies, resources and methods. Genes (Basel) 2010, 1, 70-84.
209. Pritchard, C.C.; Cheng, H.H.; Tewari, M. MicroRNA profiling: Approaches and considerations. Nat. Rev. Genet. 2012, 13, 358-369.
210. Pelaez, P.; Trejo, M.S.; Iniguez, L.P.; Estrada-Navarrete, G.; Covarrubias, A.A.; Reyes, J.L.; Sanchez, F. Identification and characterization of microRNAs in phaseolus vulgaris by high-throughput sequencing. BMC Genet. 2012, 13, 83.
211. Kong, L.; Zhu, J.; Han, W.; Jiang, X.; Xu, M.; Zhao, Y.; Dong, Q.; Pang, Z.; Guan, Q.; Gao, L., et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol. 2011, 48, 61-69.
212. Guay, C.; Regazzi, R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat. Rev. Endocrinol. 2013, 9, 513-521.
213. Farr, R.J.; Joglekar, M.V.; Taylor, C.J.; Hardikar, A.A. Circulating non-coding RNAs as biomarkers of beta cell death in diabetes. Pediatr. Endocrinol. Rev. 2013, 11, 14-20.
214. Hulsmans, M.; Holvoet, P. MicroRNAs as early biomarkers in obesity and related metabolic and cardiovascular diseases. Curr. Pharm. Des. 2013, 19, 5704-5717.
215. Takahashi, P.; Xavier, D.J.; Evangelista, A.F.; Manoel-Caetano, F.S.; Macedo, C.; Collares, C.V.; Foss-Freitas, M.C.; Foss, M.C.; Rassi, D.M.; Donadi, E.A., et al. MicroRNA expression profiling and functional annotation analysis of their targets in patients with type 1 diabetes mellitus. Gene 2014, 539, 213-223.
216. Salas-Perez, F.; Codner, E.; Valencia, E.; Pizarro, C.; Carrasco, E.; Perez-Bravo, F. MicroRNAs mir-21a and mir-93 are down regulated in peripheral blood mononuclear cells (PBMCs) from patients with type 1 diabetes. Immunobiology 2013, 218, 733-737.
217. Baran-Gale, J.; Fannin, E.E.; Kurtz, C.L.; Sethupathy, P. Beta cell 5'-shifted isomirs are candidate regulatory hubs in type 2 diabetes. PLoS ONE 2013, 8, e73240.
218. Al-Wahbi, A.M. Impact of a diabetic foot care education program on lower limb amputation rate. Vasc. Health Risk Manag. 2010, 6, 923-934.
219. Game, F.L.; Hinchliffe, R.J.; Apelqvist, J.; Armstrong, D.G.; Bakker, K.; Hartemann, A.; Londahl, M.; Price, P.E.; Jeffcoate, W.J. A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab. Res. Rev. 2012, 28, S119-S141.
220. Sieveking, D.P.; Ng, M.K. Cell therapies for therapeutic angiogenesis: Back to the bench. Vasc. Med. 2009, 14, 153-166.
221. Kirana, S.; Stratmann, B.; Prante, C.; Prohaska, W.; Koerperich, H.; Lammers, D.; Gastens, M.H.; Quast, T.; Negrean, M.; Stirban, O.A., et al. Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients. Int. J. Clin. Pract. 2012, doi:10.1111/j.1742-1241.2011.02886.x.
222. Shu, Y.; Pi, F.; Sharma, A.; Rajabi, M.; Haque, F.; Shu, D.; Leggas, M.; Evers, B.M.; Guo, P. Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Adv. Drug Deliv. Rev. 2014, 66, 74-89.
223. Park, C.Y.; Choi, Y.S.; McManus, M.T. Analysis of microRNA knockouts in mice. Hum. Mol. Genet. 2010, 19, R169-R175.
224. Ruberti, F.; Barbato, C.; Cogoni, C. Targeting microRNAs in neurons: Tools and perspectives. Exp. Neurol. 2012, 235, 419-426.
225. Van Solingen, C.; Araldi, E.; Chamorro-Jorganes, A.; Fernandez-Hernando, C.; Suarez, Y. Improved repair of dermal wounds in mice lacking microRNA-155. J. Cell Mol. Med. 2014, doi:10.1111/jcmm.12255.
226. Alipour, M.R.; Khamaneh, A.M.; Yousefzadeh, N.; Mohammad-nejad, D.; Soufi, F.G. Upregulation of microRNA-146a was not accompanied by downregulation of pro-inflammatory markers in diabetic kidney. Mol. Biol. Rep. 2013, 40, 6477-6483.
227. Guo, Q.; Zhang, J.; Li, J.; Zou, L.; Zhang, J.; Xie, Z.; Fu, X.; Jiang, S.; Chen, G.; Jia, Q., et al. Forced mir-146a expression causes autoimmune lymphoproliferative syndrome in mice via downregulation of fas in germinal center b cells. Blood 2013, 121, 4875-4883.